ASCO living guideline (version 2026.1) on systemic therapy for metastatic castration-resistant prostate cancer, kept up to date by a standing expert panel that reviews new evidence continuously. The abstract does not list the recommendations.
Guideline
Taplin et al. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1